CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom